Therapeutic management of subcutaneous phaeohyphomycosis and chromoblastomycosis in kidney transplant recipients: a retrospective study of 82 cases in a single center

Int J Dermatol. 2022 Mar;61(3):346-351. doi: 10.1111/ijd.15948. Epub 2021 Oct 11.

Abstract

Background: Melanized fungi are a distinct group of pathogens that cause infections like chromoblastomycosis and phaeohyphomycosis, especially in a state of immunosuppression including solid organ transplant recipients. Guidelines for the treatment of these infections are lacking, and there is no available standard recommendation.

Objective: To evaluate the therapeutic aspects of subcutaneous melanized fungal infections in kidney transplant recipients.

Methods: A retrospective medical record was performed for kidney transplant recipients with melanized fungal infection evaluated in a single institution from January 1996 to December 2018.

Results: Eighty-two episodes were noticed in our series. The treatment of subcutaneous phaeohyphomycosis was managed by surgical excision without antifungal therapy in 34 cases (34/68; 50%), and the association of both methods occurred in 18 cases (18/68; 26.5%). A complete surgical excision without antifungal therapy was observed in six (6/14; 42.9%) episodes of chromoblastomycosis, and combined treatment was possible in three (3/14; 21.4%) cases. Five episodes of chromoblastomycosis and 16 episodes of phaeohyphomycosis were managed only with antifungal therapy.

Conclusion: Management depends on the dermatologic lesion, immunosuppression condition, and anatomical cleavage plane. The sample size is still small in order to dictate a guideline, but it can be hard to execute a larger study given the rarity of this group of infections.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Chromoblastomycosis* / drug therapy
  • Humans
  • Kidney Transplantation* / adverse effects
  • Phaeohyphomycosis* / drug therapy
  • Retrospective Studies

Substances

  • Antifungal Agents